Therapy Areas: Diabetes
Boehringer Ingelheim, Evotec and bioMérieux Launch Aurobac Joint Venture to Fight Antimicrobial Resistance
7 July 2022 - - German biopharmaceutical company Boehringer Ingelheim, German life science company Evotec SE (Frankfurt Stock Exchange: EVT) (NASDAQ: EVO) and French diagnostics company bioMérieux have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance, the companies said.

The resulting company, Aurobac Therapeutics SAS, will combine the best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure.

The aspiration is to succeed in the fight against AMR, which is a major public health threat. Having routine surgery such as caesarean sections or hip replacements may become life threatening, and complications from common diseases such as diabetes and injuries or cuts will become harder to manage because of growing resistance to antibiotics in patients.

Aurobac will work to shift the strategy related to antibiotic treatment regimens which at the moment leans heavily on empirical approaches using broad-spectrum and unfocused medicines.

The goal is to turn this into a precision approach, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics to quickly identify pathogens and their resistance patterns, and supported by new economic models.

Funded by Boehringer Ingelheim as lead investor with EUR 30m and by Evotec and bioMérieux with EUR 5m each, the EUR 40m joint venture, which has its headquarters in Lyon (France), combines the world leading expertise of Evotec, one of the most active research companies in infectious diseases, with bioMérieux's expertise in infectious disease diagnostics and with Boehringer Ingelheim's broad drug discovery and significant clinical development capabilities.

Boehringer Ingelheim's participation in Aurobac is part of a wider so-called pandemic preparedness initiative, which includes a EUR 50m investment in the AMR action fund by Boehringer Ingelheim.

Boehringer Ingelheim Venture Fund has committed to invest up to EUR 12m in AMR infection companies.

bioMérieux has over 55 years of diagnostics expertise with more than 75% of its research and development budget focused on antimicrobial resistance.

Moreover, 80% of its turnover is related to the fight against AMR through a complete diagnostic solution facilitating antibiotic therapy decision-making, including antibiotic initiation, optimization, and discontinuation.

Evotec has built a world-leading platform to tackle infectious diseases.

With a more than 200-strong anti-infective discovery team, the company has proven experience on multiple agent classes.

On top of the company's own pre-competitive pandemic preparedness and rapid response technology platform, Evotec leverages its infectious disease capabilities with many industry, academic and non-profit partners and is active in a range of networks such as the AMR Accelerator that is part of the EU's Innovative Medicines Initiative.


Related Headlines